DAPT Score for Dual Antiplatelet Therapy Duration
Balances ischaemic benefit vs bleeding risk of prolonged dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement. Guides decision to continue or stop DAPT after 12 months.
Score interpretation
Ischaemic benefit of continuing DAPT beyond 12 months likely outweighs the bleeding risk (DAPT study).
→ Consider continuing DAPT beyond 12 months (up to 30 months in the DAPT study); weigh bleeding risk in parallel.
Bleeding risk of continuing DAPT beyond 12 months likely outweighs the ischaemic benefit.
→ Stop the P2Y12 inhibitor at 12 months and continue single antiplatelet therapy, unless another indication applies.
Interpretation bands for the DAPT Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Ticagrelor · Antiplatelet
- Clopidogrel (ACS / Post-PCI) · Antiplatelet / ACS
- Clopidogrel (Loading Dose) · P2Y12 Inhibitor Antiplatelet — ACS
- Clopidogrel (Elderly) · Antiplatelet — P2Y12 Inhibitor
- Clopidogrel (Stroke/TIA Secondary Prevention) · Antiplatelet (P2Y12 Inhibitor)
- Vorasidenib (Specialist drug) · Dual IDH1/2 inhibitor
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
